Abstract
Introduction: challenging established dogma
Highlights
Mr Dixon concluded that one would be able to measure tumour size accurately at the time of diagnosis with magnetic resonance imaging, ultrasound, or clinical measurement
Sentinel node techniques have not been used in this setting, and some concern about the use of ultrasound and fine needle aspiration (FNA) was raised during the discussion
Dr Allred concluded that some ER-negative breast cancers probably arise from ERpositive precursors, and that some ER-positive tumours arise from ER-negative cells
Summary
Mr Dixon concluded that one would be able to measure tumour size accurately at the time of diagnosis with magnetic resonance imaging, ultrasound, or clinical measurement. With accurate ultrasound and fine needle aspiration (FNA), it might be possible to detect nodal status at the time of neoadjuvant therapy. Reduction in tumour size, Ki67, or other parameters during neoadjuvant therapy might provide additional information about ultimate prognosis.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
